Novel synthetic chalcone-coumarin hybrid for Aβ aggregation reduction, antioxidation, and neuroprotection

Shin Ying Lee, Ya Jen Chiu, Shu Mei Yang, Chiung Mei Chen, Chin Chang Huang, Guey Jen Lee-Chen, Wen-Wei Lin, Kuo Hsuan Chang

Research output: Contribution to journalArticle

Abstract

Background: Aggregation of misfolded amyloid β (Aβ) in senile plaques causes oxidative stress and neuronal death in Alzheimer's disease (AD). Compounds possessing antiaggregation and antioxidant properties are promising candidate compounds for AD treatment. Methods: We examined the potential of synthetic derivatives of licochalcone A and coumarin for inhibiting Aβ aggregation, scavenging reactive oxygen species (ROS), and providing neuroprotection by using biochemical assays and Tet-On Aβ-GFP 293/SH-SY5Y cell models for AD. Results: Among test compounds, LM-031, a novel chalcone-coumarin hybrid, inhibited Aβ aggregation and scavenged free oxygen radicals. LM-031 markedly reduced Aβ misfolding and ROS as well as promoted neurite outgrowth and inhibited acetylcholinesterase in Tet-On Aβ-GFP 293/SH-SY5Y cells. Mechanistic studies showed upregulation of the HSPB1 chaperone, NRF2/NQO1/GCLC pathway, and CREB/BDNF/BCL2 pathway. Decreased neurite outgrowth upon the induction of Aβ-GFP was rescued by LM-031, which was counteracted by knockdown of HSPB1, NRF2, or CREB. Conclusion: Taken together, these findings demonstrate that LM-031 exhibited antiaggregation, antioxidant, and neuroprotective effects against Aβ toxicity by enhancing HSPB1 and the NRF2-related antioxidant pathway as well as by activating the CREB-dependent survival and antiapoptosis pathway. These results imply that LM-031 may be a new therapeutic compound for AD.

Original languageEnglish
Pages (from-to)1286-1298
Number of pages13
JournalCNS Neuroscience and Therapeutics
Volume24
Issue number12
DOIs
Publication statusPublished - 2018 Dec 1

Fingerprint

Chalcone
Alzheimer Disease
Reactive Oxygen Species
Antioxidants
Brain-Derived Neurotrophic Factor
Amyloid Plaques
Neuroprotective Agents
Acetylcholinesterase
Amyloid
Free Radicals
Oxidative Stress
Up-Regulation
Neuroprotection
coumarin
Neuronal Outgrowth

Keywords

  • Alzheimer’s disease
  • Aβ aggregation reduction
  • antioxidation
  • chalcone-coumarin hybrid
  • neuroprotection
  • therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health
  • Physiology (medical)
  • Pharmacology (medical)

Cite this

Lee, S. Y., Chiu, Y. J., Yang, S. M., Chen, C. M., Huang, C. C., Lee-Chen, G. J., ... Chang, K. H. (2018). Novel synthetic chalcone-coumarin hybrid for Aβ aggregation reduction, antioxidation, and neuroprotection. CNS Neuroscience and Therapeutics, 24(12), 1286-1298. https://doi.org/10.1111/cns.13058

Novel synthetic chalcone-coumarin hybrid for Aβ aggregation reduction, antioxidation, and neuroprotection. / Lee, Shin Ying; Chiu, Ya Jen; Yang, Shu Mei; Chen, Chiung Mei; Huang, Chin Chang; Lee-Chen, Guey Jen; Lin, Wen-Wei; Chang, Kuo Hsuan.

In: CNS Neuroscience and Therapeutics, Vol. 24, No. 12, 01.12.2018, p. 1286-1298.

Research output: Contribution to journalArticle

Lee, Shin Ying ; Chiu, Ya Jen ; Yang, Shu Mei ; Chen, Chiung Mei ; Huang, Chin Chang ; Lee-Chen, Guey Jen ; Lin, Wen-Wei ; Chang, Kuo Hsuan. / Novel synthetic chalcone-coumarin hybrid for Aβ aggregation reduction, antioxidation, and neuroprotection. In: CNS Neuroscience and Therapeutics. 2018 ; Vol. 24, No. 12. pp. 1286-1298.
@article{7f51c5164e0b4a4d8d5b58b16dc029ca,
title = "Novel synthetic chalcone-coumarin hybrid for Aβ aggregation reduction, antioxidation, and neuroprotection",
abstract = "Background: Aggregation of misfolded amyloid β (Aβ) in senile plaques causes oxidative stress and neuronal death in Alzheimer's disease (AD). Compounds possessing antiaggregation and antioxidant properties are promising candidate compounds for AD treatment. Methods: We examined the potential of synthetic derivatives of licochalcone A and coumarin for inhibiting Aβ aggregation, scavenging reactive oxygen species (ROS), and providing neuroprotection by using biochemical assays and Tet-On Aβ-GFP 293/SH-SY5Y cell models for AD. Results: Among test compounds, LM-031, a novel chalcone-coumarin hybrid, inhibited Aβ aggregation and scavenged free oxygen radicals. LM-031 markedly reduced Aβ misfolding and ROS as well as promoted neurite outgrowth and inhibited acetylcholinesterase in Tet-On Aβ-GFP 293/SH-SY5Y cells. Mechanistic studies showed upregulation of the HSPB1 chaperone, NRF2/NQO1/GCLC pathway, and CREB/BDNF/BCL2 pathway. Decreased neurite outgrowth upon the induction of Aβ-GFP was rescued by LM-031, which was counteracted by knockdown of HSPB1, NRF2, or CREB. Conclusion: Taken together, these findings demonstrate that LM-031 exhibited antiaggregation, antioxidant, and neuroprotective effects against Aβ toxicity by enhancing HSPB1 and the NRF2-related antioxidant pathway as well as by activating the CREB-dependent survival and antiapoptosis pathway. These results imply that LM-031 may be a new therapeutic compound for AD.",
keywords = "Alzheimer’s disease, Aβ aggregation reduction, antioxidation, chalcone-coumarin hybrid, neuroprotection, therapeutics",
author = "Lee, {Shin Ying} and Chiu, {Ya Jen} and Yang, {Shu Mei} and Chen, {Chiung Mei} and Huang, {Chin Chang} and Lee-Chen, {Guey Jen} and Wen-Wei Lin and Chang, {Kuo Hsuan}",
year = "2018",
month = "12",
day = "1",
doi = "10.1111/cns.13058",
language = "English",
volume = "24",
pages = "1286--1298",
journal = "CNS Neuroscience and Therapeutics",
issn = "1755-5930",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - Novel synthetic chalcone-coumarin hybrid for Aβ aggregation reduction, antioxidation, and neuroprotection

AU - Lee, Shin Ying

AU - Chiu, Ya Jen

AU - Yang, Shu Mei

AU - Chen, Chiung Mei

AU - Huang, Chin Chang

AU - Lee-Chen, Guey Jen

AU - Lin, Wen-Wei

AU - Chang, Kuo Hsuan

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Background: Aggregation of misfolded amyloid β (Aβ) in senile plaques causes oxidative stress and neuronal death in Alzheimer's disease (AD). Compounds possessing antiaggregation and antioxidant properties are promising candidate compounds for AD treatment. Methods: We examined the potential of synthetic derivatives of licochalcone A and coumarin for inhibiting Aβ aggregation, scavenging reactive oxygen species (ROS), and providing neuroprotection by using biochemical assays and Tet-On Aβ-GFP 293/SH-SY5Y cell models for AD. Results: Among test compounds, LM-031, a novel chalcone-coumarin hybrid, inhibited Aβ aggregation and scavenged free oxygen radicals. LM-031 markedly reduced Aβ misfolding and ROS as well as promoted neurite outgrowth and inhibited acetylcholinesterase in Tet-On Aβ-GFP 293/SH-SY5Y cells. Mechanistic studies showed upregulation of the HSPB1 chaperone, NRF2/NQO1/GCLC pathway, and CREB/BDNF/BCL2 pathway. Decreased neurite outgrowth upon the induction of Aβ-GFP was rescued by LM-031, which was counteracted by knockdown of HSPB1, NRF2, or CREB. Conclusion: Taken together, these findings demonstrate that LM-031 exhibited antiaggregation, antioxidant, and neuroprotective effects against Aβ toxicity by enhancing HSPB1 and the NRF2-related antioxidant pathway as well as by activating the CREB-dependent survival and antiapoptosis pathway. These results imply that LM-031 may be a new therapeutic compound for AD.

AB - Background: Aggregation of misfolded amyloid β (Aβ) in senile plaques causes oxidative stress and neuronal death in Alzheimer's disease (AD). Compounds possessing antiaggregation and antioxidant properties are promising candidate compounds for AD treatment. Methods: We examined the potential of synthetic derivatives of licochalcone A and coumarin for inhibiting Aβ aggregation, scavenging reactive oxygen species (ROS), and providing neuroprotection by using biochemical assays and Tet-On Aβ-GFP 293/SH-SY5Y cell models for AD. Results: Among test compounds, LM-031, a novel chalcone-coumarin hybrid, inhibited Aβ aggregation and scavenged free oxygen radicals. LM-031 markedly reduced Aβ misfolding and ROS as well as promoted neurite outgrowth and inhibited acetylcholinesterase in Tet-On Aβ-GFP 293/SH-SY5Y cells. Mechanistic studies showed upregulation of the HSPB1 chaperone, NRF2/NQO1/GCLC pathway, and CREB/BDNF/BCL2 pathway. Decreased neurite outgrowth upon the induction of Aβ-GFP was rescued by LM-031, which was counteracted by knockdown of HSPB1, NRF2, or CREB. Conclusion: Taken together, these findings demonstrate that LM-031 exhibited antiaggregation, antioxidant, and neuroprotective effects against Aβ toxicity by enhancing HSPB1 and the NRF2-related antioxidant pathway as well as by activating the CREB-dependent survival and antiapoptosis pathway. These results imply that LM-031 may be a new therapeutic compound for AD.

KW - Alzheimer’s disease

KW - Aβ aggregation reduction

KW - antioxidation

KW - chalcone-coumarin hybrid

KW - neuroprotection

KW - therapeutics

UR - http://www.scopus.com/inward/record.url?scp=85053454072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053454072&partnerID=8YFLogxK

U2 - 10.1111/cns.13058

DO - 10.1111/cns.13058

M3 - Article

VL - 24

SP - 1286

EP - 1298

JO - CNS Neuroscience and Therapeutics

JF - CNS Neuroscience and Therapeutics

SN - 1755-5930

IS - 12

ER -